Furthermore, diosmin promoted browning of iWAT and ameliorated hepatic steatosis with attenuated proinflammatory responses in iWAT and liver, with no apparent adverse effects such as edema or cardiovascular disease risk previously reported in PPARγ full agonist usage. This evidence concerns the gene PPARG and fatty liver disease.